Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

Richter, Anna ; Roolf, Catrin ; Hamed, Mohamed ; Gladbach, Yvonne Saara ; Sender, Sina ; Konkolefski, Christoph ; Knübel, Gudrun ; Sekora, Anett ; Fuellen, Georg ; Vollmar, Brigitte ; Murua Escobar, Hugo ; Junghanss, Christian

In: BMC Cancer, 19 (2019), Nr. 202. pp. 1-11. ISSN 1471-2407

[img]
Preview
PDF, English - main document
Download (3MB) | Lizenz: Creative Commons LizenzvertragCombined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia by Richter, Anna ; Roolf, Catrin ; Hamed, Mohamed ; Gladbach, Yvonne Saara ; Sender, Sina ; Konkolefski, Christoph ; Knübel, Gudrun ; Sekora, Anett ; Fuellen, Georg ; Vollmar, Brigitte ; Murua Escobar, Hugo ; Junghanss, Christian underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors including a subset of acute B-lymphoblastic leukemias (B-ALL). While PTEN mutations and deletions are rare in B-ALL, promoter hypermethylation and posttranslational modifications are the main pathways of PTEN inactivation. Casein Kinase II (CK2) is often upregulated in B-ALL and phosphorylates both PTEN and DNA methyltransferase 3A, resulting in increased PI3K/AKT signaling and offering a potential mechanism for further regulation of tumor-related pathways.

Methods: Here, we evaluated the effects of CK2 inhibitor CX-4945 alone and in combination with hypomethylating agent decitabine on B-ALL proliferation and PI3K/AKT pathway activation. We further investigated if CX-4945 intensified decitabine-induced hypomethylation and identified aberrantly methylated biological processes after CK2 inhibition. In vivo tumor cell proliferation in cell line and patient derived xenografts was assessed by longitudinal full body bioluminescence imaging and peripheral blood flow cytometry of NSG mice.

Results: CX-4945 incubation resulted in CK2 inhibition and PI3K pathway downregulation thereby inducing apoptosis and anti-proliferative effects. CX-4945 further affected methylation patterns of tumor-related transcription factors and regulators of cellular metabolism. No overlap with decitabine-affected genes or processes was detected. Decitabine alone revealed only modest anti-proliferative effects on B-ALL cell lines, however, if combined with CX-4945 a synergistic inhibition was observed. In vivo assessment of CX-4945 in B-ALL cell line xenografts resulted in delayed proliferation of B-ALL cells. Combination with DEC further decelerated B-ALL expansion significantly and decreased infiltration in bone marrow and spleen. Effects in patient-derived xenografts all harboring a t(4;11) translocation were heterogeneous.

Conclusions: We herein demonstrate the anti-leukemic potential of CX-4945 in synergy with decitabine in vitro as well as in vivo identifying CK2 as a potentially targetable kinase in B-ALL.

Item Type: Article
Journal or Publication Title: BMC Cancer
Volume: 19
Number: 202
Publisher: BioMed Central ; Springer
Place of Publication: London ; Berlin, Heidelberg
Date Deposited: 10 May 2019 16:04
Date: 2019
ISSN: 1471-2407
Page Range: pp. 1-11
Faculties / Institutes: Service facilities > German Cancer Research Center (DKFZ)
Subjects: 610 Medical sciences Medicine
Uncontrolled Keywords: Leukemia, CK2 inhibition, Hypomethylation, In vivo imaging, Methylome analysis
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative